Results 151 to 160 of about 360,530 (300)
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
Pingdong Cao,1 Xiao Jia,2 Yuqi Yang,1 Xi Wang,3 Jian Zhu,4 Xiaomei Li,1 Zhe Yang,1 Qiang Wen1 1Department of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan ...
Cao P +7 more
doaj
Optimizing peer review rounds in radiation oncology: a scoping review. [PDF]
Zhang J, Bayley C, Vaska M, Lee SL.
europepmc +1 more source
Report on the Veteran Health Administration: Radiation Oncology Quality and Safety Monitoring (VHA-ROQSM) Program [PDF]
Rishabh Kapoor +2 more
openalex +1 more source
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang +14 more
wiley +1 more source
The Role of Narrative Medicine in Radiation Oncology Education: A Comprehensive Review. [PDF]
Duan Q, Liu J.
europepmc +1 more source
Implementation of a programmatic assessment model in radiation oncology medical physics training [PDF]
Cathryn Barbagallo +2 more
openalex +1 more source
The versatile CaO2@CuMOF@HAP nanohybrid demonstrates an outstanding MMP9/pH‐triggered release performance for sequential release of osteogenic growth peptide into deep‐seated tumor‐infiltrated bone destruction areas and dual ions into tumor cells, enabling efficient tumor‐associated osteolysis restoration and tumor elimination for more comprehensive ...
Lan Liu +8 more
wiley +1 more source
Business Intelligence in Radiation Oncology: About Potential and Limits. [PDF]
Bovet M +3 more
europepmc +1 more source
Radiation Oncology – Towards a mission‐oriented approach to cancer [PDF]
Michaël Baumann, Carol Bacchus
openalex +1 more source
Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu +11 more
wiley +1 more source

